154 related articles for article (PubMed ID: 32805491)
1. circSETD3 Contributes to Acquired Resistance to Gefitinib in Non-Small-Cell Lung Cancer by Targeting the miR-520h/ABCG2 Pathway.
Huang Y; Dai Y; Wen C; He S; Shi J; Zhao D; Wu L; Zhou H
Mol Ther Nucleic Acids; 2020 Sep; 21():885-899. PubMed ID: 32805491
[TBL] [Abstract][Full Text] [Related]
2. New biomarker for lung cancer - focus on circSETD3.
Tao F; Gu C; Li N; Ying Y; Cao LF; Xiao QF; Ni D; Zhuang YB; Zhang Q
J Biol Regul Homeost Agents; 2021; 35(2):583-591. PubMed ID: 33768996
[TBL] [Abstract][Full Text] [Related]
3. CircRNA (circ_0008057) promotes uremic serum-mediated proliferation and migration of vascular smooth muscle cells via miR-370/PLk1 signaling pathway.
Zhang JW; Xu GY; Wang XF; Zhao YL; Kong QR
J Biol Regul Homeost Agents; 2021 Aug; 35(4):. PubMed ID: 34435479
[TBL] [Abstract][Full Text] [Related]
4. CircSETD3 mediates acquired resistance to gefitinib in non-small lung cancer cells by FXR1/ECT2 pathway.
Wen C; Li Y; Huang Y; Wang N; He S; Bao M; Zhou H; Wu L
Int J Biochem Cell Biol; 2023 Jan; 154():106344. PubMed ID: 36503048
[TBL] [Abstract][Full Text] [Related]
5. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
Wu K; Li J; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
Biomed Pharmacother; 2019 Aug; 116():108995. PubMed ID: 31121484
[TBL] [Abstract][Full Text] [Related]
6. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
8. ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC.
Zhao H; Huang Y; Shi J; Dai Y; Wu L; Zhou H
Front Pharmacol; 2018; 9():1312. PubMed ID: 30515095
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA LOC554202 promotes acquired gefitinib resistance in non-small cell lung cancer through upregulating miR-31 expression.
He J; Jin S; Zhang W; Wu D; Li J; Xu J; Gao W
J Cancer; 2019; 10(24):6003-6013. PubMed ID: 31762810
[TBL] [Abstract][Full Text] [Related]
10. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
11. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Galetti M; Petronini PG; Fumarola C; Cretella D; La Monica S; Bonelli M; Cavazzoni A; Saccani F; Caffarra C; Andreoli R; Mutti A; Tiseo M; Ardizzoni A; Alfieri RR
PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
[TBL] [Abstract][Full Text] [Related]
12. MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.
Ping W; Gao Y; Fan X; Li W; Deng Y; Fu X
Biochem Biophys Res Commun; 2018 Jan; 495(4):2482-2489. PubMed ID: 29269300
[TBL] [Abstract][Full Text] [Related]
13. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
14. Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498.
Lu M; Liu B; Xiong H; Wu F; Hu C; Liu P
J Cell Mol Med; 2019 Apr; 23(4):2431-2441. PubMed ID: 30701693
[TBL] [Abstract][Full Text] [Related]
15. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
16. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
[TBL] [Abstract][Full Text] [Related]
17. MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19.
Wang Y; Lian YM; Ge CY
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5831-5839. PubMed ID: 31298334
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer.
Lu X; Zhang Y; Pan Y; Cao M; Zhou X; Zhang T
Oncol Lett; 2021 Jan; 21(1):40. PubMed ID: 33262832
[TBL] [Abstract][Full Text] [Related]
19. lncRNA CCAT1 Acts as a MicroRNA-218 Sponge to Increase Gefitinib Resistance in NSCLC by Targeting HOXA1.
Jin X; Liu X; Zhang Z; Guan Y
Mol Ther Nucleic Acids; 2020 Mar; 19():1266-1275. PubMed ID: 32084702
[TBL] [Abstract][Full Text] [Related]
20. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Hu FY; Cao XN; Xu QZ; Deng Y; Lai SY; Ma J; Hu JB
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):839-845. PubMed ID: 27924500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
